# Performance of Wearable Pulse Oximetry During Controlled Hypoxia Induction

Authors:

Yihang Jiang[1], Connor Spies[3], Will Ke Wang[1], Ali R. Roghanizad[1], PhD, Satasuk Joy Bhosai[2,3], MD, MPH, Laurie Snyder[2,3], MD, MHS, Ashley Burke[4], David MacLeod, MB BS, FRCA[4], Jessilyn Dunn[1,5] PhD

* Corresponding Author
Email: jessilyn.dunn@duke.edu

1. Department of Biomedical Engineering, Duke University, Durham, NC, USA
2. Duke Clinical Research Institute, Durham, NC, USA
3. Department of Medicine, Duke University, Durham, NC, USA
4. Human Pharmacology & Physiology Lab, Duke University, Durham, NC, USA
5. Department of Biostatistics & Bioinformatics, Duke University, Durham, NC, USA

# Abstract

Oxygen saturation is a crucial metric used for monitoring patients with lung disease or respiratory illness who are at risk of hypoxemia (low blood oxygen saturation). Early and accurate identification of abnormal oxygen saturation is important for these patients who may develop significant desaturation and hypoxemia symptoms during their daily activities. To investigate the performance of two pulse oximeters during desaturation, we recruited nine healthy participants and performed a controlled oxygen desaturation study that reduces the blood oxygen saturation levels from 100% to 60% using a gas delivery system. We calculated the oxygen desaturation rate (ODR) of each measurement and conducted a comparative analysis of the displayed oxygen saturation readings from both the Masimo MightySat Rx finger pulse oximeter and Apple Watch Series 7 with arterial blood oxygen saturation readings obtained from a blood gas analyzer. Both the Masimo MightySat Rx pulse oximeter and the Apple Watch Series 7 tended to overestimate oxygen saturation. The pulse oximeter readings were more likely to fall within 2% of the acceptable (as specified by Masimo) peripheral oxygen saturation ($SpO_2$) error range than the Apple Watch (49.03% compared to 32.14%). Notably, both devices had limitations under low oxygen saturation levels (<88%) with an accuracy root mean square difference ($A_{rms}$) of 3.52 [3.18-3.86]% and 5.82 [5.32-6.31]% for the Masimo MightySat Rx and Apple Watch Series 7, respectively. Among the blood oxygen measurements taken during a high oxygen desaturation rate (ODR) (i.e., ≥ 2% $SpO_2$ per minute), which is a rate clinically correlated with sleep apnea, the $A_{rms}$ increased slightly by 0.75% for the Masimo MightySat Rx and decreased by 0.28% for the Apple Watch Series 7. However, no statistically significant relationship was found between the oxygen desaturation rate and the device measurement errors.

# Keywords

Pulse Oximetry; Oxygen Saturation; Smartwatches; Hypoxemia; Wearable Electronic Devices

# Introduction

Blood oxygen saturation, representing how much hemoglobin is bound with oxygen, is considered to be a useful vital sign for gaining insight into a person's health status alongside body temperature, blood pressure, heart rate, and respiratory rate(1). Chronic lung diseases such as chronic obstructive pulmonary disease(COPD) and asthma can lead to significant desaturation and hypoxemia (2,3), and exercise-induced desaturation is common in these populations and associated with increased mortality (4,5). Early and accurate identification of abnormal oxygen saturation (6) is important in patients who may develop hypoxemia symptoms and significant oxygen desaturation during exercise, rest, or sleep (7–9).

Measurement of oxygen saturation can be classified into two methods: invasive and non-invasive (10). Arterial blood gas (ABG) analysis is an invasive measurement method that requires the collection of arterial blood samples and which measures arterial oxygen saturation ($SaO_2$) by a dedicated co-oximeter machine. While ABG analysis is considered the 'gold standard', arterial blood sample collection is painful and impractical for continuous monitoring (11,12). Pulse oximetry is based on the principle that the optical absorption of light across specific wavelengths differs for oxyhemoglobin and deoxyhemoglobin and this phenomenon allows for the non-invasive estimation of blood oxygen saturation ($SpO_2$) (13). $SpO_2$ measurement functionality was first introduced in popular consumer wearables in 2021, and roughly a decade later in 2032, the global market value of wearable technology is projected to reach $191.58 billion (14). Multiple studies comparing $SpO_2$ measurements from the Apple Watch Series 7 and finger-

placed pulse oximeters found Pearson correlation coefficients ranging from 0.76 to 0.89(15–18). However, these studies did not evaluate the smartwatch's capability to detect and identify hypoxia specifically, which is when accuracy is most critical because incorrect measurements can put patients at risk of delayed recognition and treatment(19–21). Occult hypoxemia, which occurs when a person's blood oxygen level appears normal when measured by pulse oximetry ($SpO_2$ > 92%), but is actually low when measured by a more accurate test like arterial blood gas ($SaO_2$<88%), may be a clinically significant consequence of such unreliability (22). In such a situation, hypoxemia is present but "hidden" or not detected by the pulse oximeter. Occult hypoxemia is concerning because it can delay the recognition and treatment of low oxygen levels, especially in critically ill patients or those with respiratory diseases like COVID-19.

Additionally, while $SpO_2$ is often straightforward to measure when its level has reached a steady state, challenges arise in trying to accurately measure $SpO_2$ under dynamic change, and particularly when those changes are rapid such as during sleep apnea (23,24). Blood oxygen levels typically decrease in people with obstructive sleep apnea (OSA) as a result of gaps in their breathing (25). The oxygen desaturation rate (ODR), defined as the change in $SpO_2$ per minute, is a metric used to quantify such changes in $SpO_2$ over time. During rapid desaturation, pulse oximeter accuracy has been shown to decrease due to the averaging-window algorithms that smooth the signal over several seconds and include values before the desaturation event(26,27), causing the reported $SpO_2$ value to lag behind the patient's real-time oxygenation status and resulting in incorrect values. Because pulse oximeter accuracy may be mediated by the ODR, it is important to evaluate pulse oximeter performance under conditions of rapid oxygen desaturation. While such studies have been performed in the past, they typically do not use the

gold standard $SaO_2$ method to measure blood oxygen saturation due to its burdensome nature of sample collection (28–30). In this study, we evaluated whether the accuracies of $SpO_2$ measurements from a common pulse oximeter and a smartwatch were impacted by the ODR using gold standard $SaO_2$ measurements.

# Materials and Methods

## Ethical Considerations

This study was approved by the Duke University Health System (DUHS) Institutional Review Board (Pro00110458). Written informed consent was obtained from participants prior to their participation in the study.

## Study Population

This study was conducted as an opportunistic investigation embedded within an existing controlled hypoxia study, which involved invasive arterial catheterization and prolonged exposure to reduced oxygen levels. As a result, the number of participants was constrained by the requirements of the parent study. Inclusion criteria included healthy male or female subjects between the ages of 18 and 45 years with a minimum body weight of 40 kg and a body mass index between 18.0 and 35.0 kg/m². Individuals were excluded if they had peripheral vascular disease, Raynaud's syndrome, cryoglobulinemia, or any collagen vascular disease affecting the fingers; a history of blood clots within the past six months; a history of sickle cell trait or thalassemia; a positive urine cotinine test; heparin allergy; essential tremor; gel nail polish or any other non-natural, non-removable discoloration of the forefinger; and, based on venous blood

sampling, abnormal hemoglobin levels, abnormal hemoglobin electrophoresis, carboxyhemoglobin levels greater than 3 g/dL, or methemoglobin levels greater than 2 g/dL.

## Equipment

Equipment was used in this study to assess skin tone, control the desaturation process, and take the $SpO_2$ and arterial oxygen saturation ($SaO_2$) measurements. To assess skin tone, the Delfin SkinColorCatch colorimeter was used to report the Individual Typology Angle (ITA) which classifies skin color types into six groups, from Very Light to Dark skin: Very Light (>55°), Light (41° to <55°), Intermediate (28° to <41°), Tan (10° to <28°), Brown (-30° to <10°) and Dark (<-30°). In the desaturation process, we used the sequential gas delivery system RespirAct RA-MR to control the alveolar oxygen tension ($PAO_2$) and partial pressure of end-tidal oxygen ($PetO_2$) by changing inhaled oxygen and carbon dioxide levels (31). The attained $PAO_2$ determined the partial pressure of oxygen in arterial blood ($PaO_2$) at the alveolar-arterial interspace in the lung. The $PaO_2$ in turn determined the participants' $SaO_2$ prior to blood gas sampling. The Radiometer ABL90 Flex blood gas analyzer was used to analyze extracted arterial blood gas samples and obtain the functional arterial oxygen saturation. The Apple Watch Series 7 smartwatch (reflectance pulse oximeter) and Masimo MightySat Rx finger pulse oximeter (transmissive pulse oximeter) were each used to measure $SpO_2$ separately. The Apple Watch Series 7 was chosen as it was previously identified to have the best performance among a selection of four commercial wearables in an analytic validation study (15,32,33), and the Masimo MightySat Rx was chosen because it is a FDA 510(k) cleared pulse oximeter (34,35).

## Desaturation Protocol

In this study, we employed a controlled gas delivery system to conduct the controlled desaturation protocol and altered the $SaO_2$ by adjusting end-tidal oxygen ($PetO_2$) levels that participants inhaled (Figure 1). We then compared the oxygen saturation ($SpO_2$) measurements from Apple Watch Series 7 and the Masimo MightySat Rx against the gold standard ABG measurements.




**Figure 1.** Workflow of the equipment used to adjust $PetO_2$ and to measure $SaO_2$. Adjusting the end-tidal $PetO_2$ setting in the RespirAct RA-MR gas delivery system (A) led the study participant to inhale gas with different oxygen, carbon dioxide and nitrogen concentrations through a fitted mask (B). Blood samples taken once the $PetO_2$ stabilized were processed by a blood gas analyzer (Radiometer ABL90 Flex) (C) to measure the resulting $SaO_2$ and $PaO_2$.

Before the desaturation procedure, participants laid in the supine position on a standard hospital stretcher with an arterial catheter placed in the forearm for blood sampling. The facemask that was connected to the sequential gas delivery system donned by the participant. The Apple Watch Series 7 was placed comfortably but tight enough on the right wrist, approximately one centimeter above the ulnar styloid process, to avoid movement during the experiment. The Masimo MightySat Rx was placed on the middle finger of the participant's right hand.

This study involved three phases: a sequential, stepwise oxygen desaturation phase with monotonically decreasing oxygen saturation (Figure 2A, Phase 1), an oxygen saturation recovery phase (Figure 2A, Phase 2), and an interrupted oxygen desaturation phase which included a brief increase in blood oxygen saturation during the overall desaturation sequence which enables evaluation of pulse oximeters during directional changes in blood oxygen saturation (e.g., desaturation to resaturation or resaturation to desaturation) (Figure 2A, Phase 3). Besides the oxygen saturation recovery phase, Phase 1 was designed to follow a standard step-down sequence (34), as recommended by FDA, for assessing the performance of pulse oximeters during desaturation and hypoxemia while Phase 3 was designed to evaluate device performance when the desaturation was interrupted under hypoxemia. Blood oxygen levels ($SaO_2$) were altered by controlling inhaled oxygen and carbon dioxide levels using the RespirAct gas delivery system, which correspondingly altered $PaO_2$ and $PetO_2$, in turn, $SaO_2$ (36). In the first sequence, the oxygen saturation ($SaO_2$) was reduced in stepwise fashion from ~100% to ~60%, and then back to ~100% over the course of approximately 24 minutes. The second sequence involved holding participants' $SaO_2$ at ~100% for approximately 30 minutes. The third sequence involved decreasing participants' $SaO_2$ from ~100% to ~80%, then back to ~100% over the course of 21 minutes. The first oxygen desaturation sequence (Figure 2A, Phase 1) involved 8 steps of approximately 3 minutes each with $PetO_2$ set to 90, 60, 50, 45, 40, 37, 34, 32, and 250 mmHg. Using the Severinghaus formula (37), $SaO_2$ levels at these stages were estimated to be 97%, 90%, 85%, 81%, 75%, 70%, 65%, 60% and 100%, respectively. Following this sequence, $PetO_2$ was held at 250 mmHg for approximately 30 minutes to allow participants to recover their maximum oxygen saturation (Figure 2A, Phase 2). The final oxygen desaturation sequence (Figure 2A, Phase 3) consisted of 7 steps of approximately 3 minutes each with $PetO_2$ set to 90, 60, 50, 60, 50,

45, 40 and 250 mmHg, corresponding to an estimated $SaO_2$ of 97%, 90%, 85%, 90%, 85%, 80%, 75% and 100%. During each step of the sequence, PetO□ was held at a steady state using the RespirAct RA-MR until two ABG samples were obtained: one collected once PetO□ had stabilized, and another collected one minute later, right before transitioning to the next target PetO□ level. Consecutive plateaus were separated by approximately two minutes to allow the gas delivery system to reach the next target PetO□ level. The only exception was the recovery period between Phase 2 and Phase 3, during which participants were given a 30-minute rest interval. A participant who completes the full desaturation protocol is expected to have 36 ABG samples corresponding to two samples at each of the 18 steady-state plateaus, which themselves comprised eight plateaus during Phase 1 (initial desaturation), two plateaus during Phase 2 (recovery at high PetO□), and eight plateaus during Phase 3 (interrupted desaturation).

Two measurements of $SpO_2$, one each from the Apple Watch Series 7 and the Masimo MightySat Rx, were obtained simultaneously with each ABG sample at each steady-state plateau. Measurements on the smartwatch were manually triggered and the participants were instructed to keep their arm still during the 15-second countdown while awaiting the $SpO_2$ reading. The finger pulse oximeter reading was recorded once the smartwatch produced either a successful or unsuccessful measurement. If Masimo MightySat Rx or Apple Watch Series 7 failed to produce a measurement, we recorded a missing (invalid) measurement and made another attempt after readjusting the device. If both devices successfully produced readings, the smartwatch was manually triggered again to initiate the second measurement.

## Metrics and statistical analysis

To assess the performance of the MightySat Rx and Apple Watch Series 7, we compared each $SpO_2$ measurement to the $SaO_2$ measurements, determining if they fell within, above, or below the acceptable error range (2%) as defined by the Masimo MightySat Rx manual. We also recorded whether the $SpO_2$ measurements were missing, indicating that the pulse oximetry device was unable to generate a measurement. The Bland-Altman method was employed to assess the accuracy of $SpO_2$ measurements across all readings, with separate analysis for readings where the $SaO_2$ value was below 88%. The threshold of 88% was chosen in line with the British Thoracic Society guidelines (31) indicating the decision point for implementing intensive therapy to elevate oxygen saturation. The x-axes of the Bland-Altman plot are the mean of the $SaO_2$ and $SpO_2$ values and the y-axes are the difference between $SaO_2$ and $SpO_2$. Metrics to gauge each device's performance included: Mean directional error (MDE) (Eq 1), missingness (Eq 2) and average root mean square difference ($A_{rms}$) (Eq 3) where p is the number of participants and $v_i$ is the number of valid measurements for the $i^{th}$ participant. To evaluate device performance during oxygen desaturation, we excluded measurements with $SpO_2$ or $SaO_2$ >99% (n=57) as well as measurements collected during the resaturation process (n=79), which was defined by an increase in SaO□ relative to the preceding measurement (i.e., between Phase 1 and Phase 2 of the protocol). For the remaining measurements (n=172) with ODR ≥ 2%/min or <2%/min, we utilized a two-sided paired t-test to examine the hypothesis that MDE differs between the two ODR scenarios. The choice of 2%/min stems from the 4% oxygen desaturation index (ODI-4%), which is defined as the number of events per hour with a more than 4% decrease in $SpO_2$ within two minutes (i.e., the equivalent of an average of a two percent change per minute)(24). ODI-4% is a clinically important metric to help diagnose obstructive sleep

apnea (38). However, because the sampling frequency of the $SaO_2$ measurements is less than one measurement every two minutes, we thus translated this threshold into an ODR of 2%/min. Before our statistical testing, the differences between each pair of SpO□ and SaO□ point measurements (see supplemental Table 1) were mean-aggregated for each person at each of the two ODRs, resulting in one MDE per person per ODR scenario. This was done separately for the Apple Watch Series 7 and for the Masimo MightySat Rx SpO□ measurements. These calculations resulted in nine participant-level MDE values for each ODR scenario and for each device (see Supplementary Table 1, column 7; Supplementary Figure 1; see Supplementary Figure 2 for normality check). Two paired t-tests were performed separately, one for each device, on the nine MDE values when ODR≥ 2%/min and the nine MDE values when ODR < 2%/min to determine whether MDE values were statistically significantly different when ODR was above or below 2%/min.

$$\text{MDE (Mean directional error)} = \frac{\sum_{i=1}^{p}\sum_{j=1}^{v_i}(\text{SpO}_{2\,i,j}-\text{SaO}_{2\,i,j})}{\sum_{i=1}^{p} v_i} \quad (1)$$

$$\text{Missingness}(\%) = 100 - \left(\frac{\sum_{i=1}^{p} v_i}{\text{Total measurements}}\right) * 100 \quad (2)$$

$$A_{rms}\ \text{(Root mean square difference)} = \sqrt{\frac{\sum_{i=1}^{p}\sum_{j=1}^{v_i}(\text{SpO}_{2\,i,j}-\text{SaO}_{2\,i,j})^2}{\sum_{i=1}^{p} v_i}} \quad (3)$$

# Results

## Study Population

Nine individuals, five males and four females, provided written informed consent following the Duke University Health System IRB protocol (Pro00110458) and completed the study as described in the Methods. The ITA values of all participants ranged from -27° to 54°, with a median value of 7° (Table 1).

**Table 1. Participant demographics and characteristics**

| Participant Number | ITA value | Reference ITA skin classification (39,40) |
|---|---|---|
| 1 | 23 | Tan |
| 2 | 54 | Light |
| 3 | -27 | Brown |
| 4 | -8 | Brown |
| 5 | 12 | Tan |
| 6 | 39 | Intermediate |
| 7 | 2 | Brown |
| 8 | -1 | Brown |
| 9 | 7 | Brown |

## Comparison between Arterial Blood Gas and Pulse Oximetry Measurements

Measurements were taken across 9 study participants at 18 set $PetO_2$ levels ranging from 32 to 250 mmHg, which translates to an approximate $SaO_2$ from 60% to 100% over the course of three phases of the study that involved monotonic oxygen desaturation, recovery, and interrupted

oxygen desaturation (Figure 2A; a representative participant's trajectory is shown in Figure 2D). There were 308 measurements of the "ground truth" ABG-based blood oxygen saturation ($SaO_2$) which were compared with the $SpO_2$ measurements generated by the Masimo MightySat Rx (Figure 2B) and the Apple Watch Series 7 (Figure 2C). All participants had maximum ABG-based $SaO_2$ measurements of 99% and maximum Masimo- and Apple watch-based $SpO_2$ measurements of 100% (Table 2). The minimum $SaO_2$ was less than 65% for 6 out of 9 (67%) participants, and minimum $SpO_2$ was less than 65% for 7 out of 9 (78%) participants using the Masimo MightySat Rx and for 2 out of 9 (22%) participants using the Apple Watch Series 7. In general, the Apple Watch Series 7 measurements did not reach the same nadir values as the Masimo MightySat Rx measurements (Figure 2B and 2C).




**Figure 2. (A)** Severinghaus-estimated $SaO_2$ values. The solid blue dots represent the estimated $SaO_2$ based on the $PetO_2$ settings at each step of the protocol, and the solid lines show the overall

trajectories. The three phases of the study protocol (1: oxygen desaturation; 2: oxygen saturation recovery; 3: interrupted oxygen desaturation) are separated using gray vertical lines. **(B and C)** Actual $SpO_2$ measurements from the Masimo MightySat Rx (B) and the Apple Watch Series 7 (C) throughout the study protocol (N=9 study participants). (**D**) Actual SpO□ and SaO□ measurements from a representative participant resulting from the changing PetO□ in the inhaled gas mixture over the duration of the study.

**Table 2. The Maximum and Minimum $SpO_2$ and $SaO_2$ Values and their interindividual ranges during the Desaturation Procedure**

| Type of measurements | Maximum (%) [range] | Minimum (%) [range] |
|---|---|---|
| $SpO_2$ measurements from Masimo MightySat Rx | 100 [100 - 100] | 53 [53 - 71] |
| $SpO_2$ measurements from Apple Watch Series 7 | 100 [100 - 100] | 61 [61 - 85] |
| $SaO_2$ measurements | 99.8 [99.2 - 99.8] | 56.0 [56.0 - 70.0] |

Each measurement from the Masimo MightySat Rx and the Apple Watch Series 7 was compared to its concomitant ABG measurement to determine whether it fell within, above, or below 2% error, which was the acceptable range as defined by the Masimo MightySat Rx manual. The percentage of measurements falling into these different categories demonstrates whether there exists a trend of over- or underestimation of $SpO_2$ levels. Both the MightySat Rx and the Apple Watch Series 7 tended to overestimate $SpO_2$ with mean directional errors (MDE) of 1.80% and 3.26%, respectively (Figure 4, Figure 4A, Figure 4B). The Apple Watch Series 7 had a higher proportion of overestimated measurements (56.49% of $SpO_2$ measurements were overestimated) as compared with the MightySat Rx (where 44.48% of measurements were overestimated). A

higher percentage of Masimo MightySat Rx $SpO_2$ measurements (49.03%) fell within the 2% error range of the reference $SaO_2$ values compared to Apple Watch Series 7 $SpO_2$ measurements (32.14%).

Arms across 5% $SaO_2$ bins demonstrated a decreasing trend (Figure 3) for both devices with increasing $SaO_2$. The highest Arms values were observed at the lowest saturation ranges (60–65%), reaching 7.26% for the Apple Watch Series 7 and 4.57% for the Masimo MightySat Rx. In contrast, the lowest Arms values occurred at the highest saturation range (95–100%), where Arms decreased to 2.27% for the Apple Watch Series 7 and 1.53% for the Masimo MightySat Rx. Overall, the Masimo MightySat Rx exhibited lower Arms values than the Apple Watch Series.




**Figure 3.** $A_{rms}$ of $SpO_2$ measurements for Apple Watch Series 7 (red) and Masimo MightySat Rx (blue) binned by 5% oxygen saturation bins ranging from 60% to 100%. Points indicate the $A_{rms}$ within each SaO□ range, and error bars represent the 95% confidence intervals.

A Bland–Altman analysis demonstrated that $SpO_2$ measurements tended to be overestimated since the points in the figure mostly lie above the zero-bias line (Figure 4A, Figure 4B). Overall,

the Masimo MightySat Rx showed higher accuracy against the $SaO_2$ ground truth measures than the Apple Watch Series 7, with an average root mean square difference in accuracy ($A_{rms}$) [95% CI] of 2.98 [2.72-3.25]% for the Masimo MightySat Rx and 4.63 [4.26-5.00]% for the Apple Watch Series 7.




**Figure 4.** Bland-Altman plots demonstrate the differences between simultaneous ABG-based $SaO_2$ measurements and either all (A) or hypoxemia-only ($SaO_2$ < 88 %) (C) $SpO_2$ measurements from the Apple Watch Series 7. The same comparisons are shown between $SaO_2$ and $SpO_2$ for the Masimo MightySat Rx (all, B; and hypoxemia-only, D). The solid line shows the mean difference of the measurements (MDE) and the dashed lines show the 95% limits of agreement.

## Missingness Evaluation

Of attempted $SpO_2$ measurements, 305 out of 308 (99%) and 284 out of 308 (92%) were successfully reported by the Masimo MightySat Rx and Apple Watch Series 7, respectively. In

other words, when the device was prompted to make a measurement, the Masimo MightySat Rx was unable to produce three out of 308 attempted measurements, while the Apple Watch Series 7 was unable to produce 24 out of 308 attempted measurements (Figure 5, blue bar). Thus, in terms of missingness, the Apple Watch Series 7 had more missingness (7.79%) compared to the MightySat Rx (0.97%), indicating that both have high likelihood (>90%) for successfully obtaining a measurement when a measurement was attempted.




**Figure 5.** Relative percentages of data falling into the categories of overestimated measurements (green), measurements within acceptable error ranges (yellow), underestimated measurements (red), and missing measurements (blue) for the Masimo MightySat Rx and Apple Watch Series 7.

## Accuracy of measurements under hypoxemia

The clinical threshold for hypoxemia is blood oxygen saturation < 88% (41). As noted in the introduction, occult hypoxemia is a situation where a patient actually has blood oxygen saturation < 88%, but their blood oxygen saturation measurements read as higher (i.e., above the

threshold that would lead to a clinical intervention). Among the 308 ABG-based $SaO_2$ measurements, 165 (54%) were < 88%. Among those, the Masimo MightySat Rx and Apple Watch Series 7 produced 164 (99%) and 150 (91%) simultaneous $SpO_2$ measurements, respectively– the remaining were attempted but the devices did not generate values and thus those values were considered missing. Among those $SpO_2$ measurements where $SaO_2$ was less than 88%, 86/164 (52.44%) of the Masimo MightySat Rx measurements and 128/150 (85.33%) of the Apple Watch Series 7 measurements were overestimated. Importantly, 3 (1.8%) of the Masimo MightySat Rx measurements and 6 (4.0%) of the Apple Watch Series 7 measurements were actually reported to be above 92%. These instances of occult hypoxemia occurred in participants 2 and 7 using the Masimo MightySat Rx, and in participants 2, 8, and 9 using the Apple Watch Series 7. Notably, only one measurement from a single participant (participant #2) demonstrated an instance of occult hypoxemia that was detected simultaneously on both devices.

Looking specifically under conditions of hypoxemia, the MDE of $SpO_2$ for the Masimo MightySat Rx and the Apple Watch Series 7 was 1.96% and 4.99%, respectively– higher than the overall MDE of 1.80% and 3.26% reported above (Figure 4C, Figure 4D; Supplementary Table 1, which represents participant-level MDE of $SpO_2$ for Masimo MightySat Rx and the Apple Watch Series 7). The $A_{rms}$ [95% CI] during hypoxemia was 3.52 [3.15-3.87]% and 5.82 [5.34-6.30]% $SpO_2$ for the Masimo MightySat Rx and the Apple Watch Series 7, respectively, which are also both higher than the overall $A_{rms}$.

## Relationship between device performance and oxygen desaturation rate (ODR)

Before comparing device performance under ODR ≥ 2%/min and ODR < 2%/min conditions, we excluded 57 fully saturated measurements (SpO□ or SaO□ > 99%) and 79 resaturation measurements. Among the remaining 172 desaturating SaO□ measurements (Supplementary Table 1) out of the total 308 measurements, 169 and 157 SpO□ measurements were collected from the Masimo MightySat Rx and the Apple Watch Series 7, respectively. Among those, 83/169 Masimo MightySat Rx and 78/157 Apple Watch Series 7 measurements occurred when the ODR was greater than two percent per minute.

When the ODR increased above 2%/min, the Masimo MightySat Rx $A_{rms}$ increased from 3.04% to 3.79% and the MDE increased from 1.86% to 2.38%. Also at ODR>2%/min, the Apple Watch Series 7 MDE increased from 4.16% to 4.41% (Supplementary Figure 2) but $A_{rms}$ decreased from 5.50% to 5.22%. No significant correlation was found (Figure 6) between the ODR and MDE for the Masimo MightySat Rx nor the Apple Watch (two-sided paired t-test: P = 0.12 and 0.22, respectively).



**Figure 6.** Boxplots demonstrate the participant-level MDEs of (A) Masimo MightySat Rx and (B) Apple Watch Series 7 between $SpO_2$ and $SaO_2$ measurements when oxygen desaturation rate ≥ 2%/min and < 2%/min.

# Discussion

We designed and implemented this study to evaluate the performance of optical blood oxygen saturation measurements ($SpO_2$) from smartwatches and finger pulse oximeters under conditions of hypoxemia that were induced by a controlled oxygen desaturation protocol. There are three main findings of our study: (1) Both the Masimo MightySat Rx and the Apple Watch Series 7 often overestimate true blood oxygen saturation values, with 44% and 56% of their measurements in this study, respectively, found to be higher than the ground truth $SaO_2$ measures; (2) Both devices have lower accuracy during hypoxemia than at normal blood oxygen saturation; (3) Both devices showed a trend toward lower accuracy when the ODR is larger than 2%/minute but the difference is not statistically significant.

Our previous study (32), which used the Masimo MightySat Rx as the reference measurement for oxygen saturation to analytically validate four commercial wearables in 49 patients with low blood oxygen saturation, many of whom had chronic pulmonary disease, found that the Apple Watch Series 7 overestimated blood oxygen saturation measurements 17% of the time. In this current study, where we used ABG measurements of $SaO_2$ as the reference standard "ground truth" measure, as well as a controlled oxygen desaturation study protocol in healthy individuals to achieve low blood oxygen saturation, the Apple Watch Series 7 overestimated blood oxygen saturation 56% of the time. In this study, we also observed that the Masimo MightySat Rx, the

reference standard used in the previous study, also overestimated oxygen saturation levels 44% of the time. One likely reason for the discrepancy in the Apple Watch Series 7 overestimation rate between the two studies is the choice of the reference standard measurement – the ABG measurements used in the current study are a more trustworthy ground truth measurement. Another likely factor is the difference in the distribution of oxygen saturation values between the two studies. Specifically, our previous study did not include a desaturation protocol, and the SpO□ measurements obtained from the Masimo MightySat Rx ranged only from 82% to 100%, which may have contributed to a lower observed rate of overestimation. Blood oxygen saturation overestimation is particularly dangerous under conditions of occult hypoxemia (where the actual $SaO_2$ is < 88% but the measured $SpO_2$ is > 92%), when a patient's blood oxygen saturation is thought to be normal and care is delayed (42). In our study, although the Apple Watch Series 7 had a high rate of overestimation (56% of measurements), only 6/150 (4.0%) of the Apple Watch Series 7 measurements and 3/164 (1.8%) of the Masimo MightySat Rx measurements actually fell into the category of occult hypoxemia. It is likely that, had there been more measurements concentrated only slightly below 88%, there would have been more occurrences of occult hypoxemia observed in our study. This is because the mean bias of the Apple Watch Series 7 measurements under hypoxemia conditions (4.99%) just slightly exceeds the minimum difference (4%) between $SpO_2$ and $SaO_2$ that defines occult hypoxemia (92% vs 88%).

Our study also demonstrates that the performance of both the finger pulse oximeter and the smartwatch suffers during hypoxemia as compared to conditions of normal blood oxygen saturation. The overestimation rate increased from 44.48% to 52.44% for the Masimo MightySat Rx and from 56.49% to 85.33% for the Apple Watch Series 7 while the $A_{rms}$ increased from 2.98%

to 3.52% and 4.63% to 5.82% during hypoxemia for the two devices, respectively. For 510(k) clearance, the FDA currently recommends an $A_{rms}$ of <3.0% for transmission pulse oximeters (e.g., Masimo MightySat Rx) and <3.5% for reflectance oximeters (e.g., Apple Watch) (34). According to the FDA's 2025 draft guidance, the $A_{rms}$ specification for both sensor types will be standardized to <3.0% (43). Both devices used in our study exhibited $A_{rms}$ values exceeding the FDA threshold under conditions of hypoxemia. A previous study that recruited 50 healthy adults and conducted oxygen desaturation cycles from approximately 100% to 70% SaO□ evaluated the accuracy of Apple Watch SpO□ measurements using ABG as the gold standard; this study also reported a trend of overestimation in the Apple Watch Series 6, with an Arms of 2.18% (95% CI: 1.55–2.84%), meeting current or upcoming FDA Arms requirements. The missingness in their study was 5.29% (964 of 1020 attempted measurements gave readings) as compared with 7.79% (284 of 308 attempted measurements gave readings) in our study, likely due to more measurements in our study attempted at lower oxygen saturation (44). Another study involving 167 participants with acute exacerbation of COPD reported an MDE of 0.46% between Apple Watch Series 6 measurements and ABG-based $SaO_2$ measurements (30).

When the ODR exceeded 2%/min, $A_{rms}$ increased from 3.04% to 3.79% for the Masimo MightySat Rx and decreased from 5.50% to 5.22% for the Apple Watch Series 7. Even though the difference between $SaO_2$ and $SpO_2$ was not found to be statistically significant during desaturation, the fact that $A_{rms}$ exceeded 3% for both devices indicates that they should be used with caution, particularly under rapid desaturation conditions. Accurate performance during oxygen desaturation is crucial not only for monitoring oxygen levels but also for clinical decision making. This finding is especially relevant for home monitoring in patients with obstructive

sleep apnea, where the number of desaturation episodes (i.e., a drop in mean oxygen saturation of ≥ 4% over the course of 120 seconds) is linked to apnea and hypopnea (24). Inaccuracies and missingness during desaturation could result in misclassification of these episodes, leading to inappropriate assessment and treatment plans for patients.

Although current FDA guidance recommends validation of pulse oximeter accuracy within the SpO□ range of 70% to 100%, our results highlight the importance of evaluating device performance at lower oxygen saturation levels. Device accuracy declined substantially as SaO□ decreased from 100% to 60%, with Arms increasing from 2.27% to 7.26% for the Apple Watch Series 7 and from 1.53% to 4.57% for the Masimo MightySat Rx. These results suggest that limiting validation to SpO□ values ≥70% may overlook performance limitations in more severe hypoxemia, where accurate measurement is critical for timely clinical interventions. Expanding regulatory validation requirements to include lower saturation ranges may therefore provide a more comprehensive assessment of pulse oximeter performance.

## Limitations

The main limitation of this study is the small sample size, which resulted in insufficient representation across skin tone categories and age ranges. According to the FDA guidance for pulse oximeters, 10 or more healthy participants that vary in age and gender should be included and a minimum of 2 subjects, or 15% of the study participant pool, need to be darkly pigmented (34). However, in our study, only four (light, intermediate, tan, brown) out of the seven possible ITA skin types (very light, light, intermediate, tan, brown, dark and very dark) were represented. A benefit of our study, however, was the use of objective skin tone measures using a device

rather than the more common subjective human assessment using a comparison scale like Fitzpatrick or Monk (Supplementary Figure 4). Moreover, only the brown and tan skin types were represented by more than one participant, and we did not have any representation from the dark, very dark, and very light categories. This lack of diversity across skin tones limits the generalizability of our findings to individuals with lighter or darker skin tones. We recognize this as a limitation in our study as a result of the limited time and resources available to perform the study more comprehensively.

While our study captured a wide range of oxygen saturation values from 60% to 100%, covering the FDA-recommended SpO accuracy validation range of 70% to 100%, we did not measure the response time of the finger pulse oximeter, and the Apple Watch Series 7 reported $SpO_2$ readings after a fixed 15-second countdown. Previous studies have shown that finger pulse oximeters may have a delay in displaying the blood oxygen saturation values during the onset of hypoxia (45). Several factors can contribute to this delay, including the measurement site and poor peripheral perfusion (45). Other research suggests that fingertip oximeters have the slowest response in desaturation changes from normoxemia to hypoxemia (46). Future studies could consider evaluating the response time during desaturation events to ensure that pulse oximeters provide not only accurate but also timely measurements.

Although our experiment simulated the process of oxygen desaturation in healthy participants, there are additional factors to consider that may prevent these results from generalizing to patients of older age and/or who may experience oxygen desaturation as a result of a health condition. The age range of our study participants was between 19 and 28 years, COPD is most

prevalent in people aged 65–84 (47). Arterial stiffness of older people results in changes in the propagation of the pulse to the periphery, thereby influencing the peripheral pulse timing and shape characteristics which can affect the performance of pulse oximeters (48).

Finally, this protocol cannot demonstrate $SpO_2$ measurement performance over long periods since each participant only spent 60 minutes in the first oxygen desaturation sequence and 48 minutes in the second one. While it would be infeasible to induce oxygen desaturation for such a long period in healthy adults, clinically, it is necessary to be able to consistently monitor oxygen saturation values overnight, for example in COPD patients who often experience nocturnal hypoxemia (2,49). It is therefore necessary to perform clinical validation among COPD patients with nocturnal desaturation, defined as having a $SpO_2$ value below 90% for more than 30% of the time in bed during one or more nights (50,51). Future clinical validation studies should thus perform real world monitoring over longer periods, and particularly during sleep, in COPD and sleep apnea patients to capture nocturnal desaturation caused by those conditions (52).

# Conclusion

In this controlled hypoxemia study, we evaluated how well the Masimo MightySat Rx and the Apple Watch Series 7 oxygen saturation measurements (SpO□) correspond to arterial blood gas measurements (SaO□) across a range of arterial oxygen saturation levels, ranging from approximately 60% to 100%. Both devices consistently overestimated SpO□, with accuracy declining notably during hypoxemia. The Apple Watch Series 7 mean bias suggests a likelihood for missing instances of hypoxemia, particularly at SaO□ values below, but close to, 88%. Both

the Apple Watch Series 7 and Masimo MightySat Rx exhibited $A_{rms}$ values exceeding the FDA threshold under conditions of hypoxemia. While past studies have implicated high oxygen desaturation rates in increasing measurement error, we found no statistically significant relationship between ODR and measurement error for either device. Overall, our findings of SpO□ overestimation and high $A_{rms}$ values underscore the need for caution when interpreting oxygen saturation values from these devices. The small sample size and limited diversity in skin tone and age restrict the generalizability of our findings. Future studies should include larger and more diverse populations to evaluate the performance of wearable-based pulse oximetry.


# Acknowledgements

This study was supported in part by funds from AstraZeneca (LS and SJB), by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (R01DK133531 to JD), and by NSF CAREER #2339669. The content is solely the responsibility of the authors and does not necessarily represent the official views of AstraZeneca or the National Institutes of Health.


# Conflicts of Interest

JD sits on the Google Consumer Health Advisory Board and is a consultant to Samsung Research America and Jones Day.

# Data Availability

The datasets analyzed during this study are available from the corresponding author upon reasonable request.

# Abbreviations

$A_{rms}$: Average Root Mean Square
$SpO_2$: Peripheral oxygen saturation
$SaO_2$: Arterial oxygen saturation
$PetO_2$: Partial pressure of end-tidal oxygen
$PAO_2$: Alveolar oxygen tension
$PaO_2$: Partial pressure of oxygen in arterial blood
ABG: Arterial blood gas
ODR: Oxygen desaturation rate

# References


1. Pulse Oximetry > Fact Sheets > Yale Medicine [Internet]. [cited 2023 Dec 12]. Available from: https://www.yalemedicine.org/conditions/pulse-oximetry

2. Soguel Schenkel N, Burdet L, de Muralt B, Fitting JW. Oxygen saturation during daily activities in chronic obstructive pulmonary disease. Eur Respir J. 1996 Dec;9(12):2584–9.

3. Inwald D, Roland M, Kuitert L, McKenzie SA, Petros A. Oxygen treatment for acute severe asthma. BMJ. 2001 Jul 14;323(7304):98–100.

4. Panos RJ, Eschenbacher W. Exertional Desaturation in Patients with Chronic Obstructive Pulmonary Disease. COPD: Journal of Chronic Obstructive Pulmonary Disease. 2009 Nov 25;6(6):478–87.

5. Dogra AC, Gupta U, Sarkar M, Padam A. Exercise-induced desaturation in patients with chronic obstructive pulmonary disease on six-minute walk test. Lung India. 2015;32(4):320–5.

6. Vold ML, Aasebø U, Wilsgaard T, Melbye H. Low oxygen saturation and mortality in an adult cohort: the Tromsø study. BMC Pulm Med. 2015 Feb 12;15:9.

7. Davis J. WebMD. [cited 2023 Dec 12]. What Is COPD Hypoxia? Available from: https://www.webmd.com/lung/copd/copd-hypoxia

8. Knower MT, Dunagan DP, Adair NE, Chin J Robert. Baseline Oxygen Saturation Predicts Exercise Desaturation Below Prescription Threshold in Patients With Chronic Obstructive Pulmonary Disease. Archives of Internal Medicine. 2001 Mar 12;161(5):732–6.

9. Little SA, Elkholy MM, Chalmers GW, Farouk A, Patel KR, Thomson NC. Predictors of nocturnal oxygen desaturation in patients with COPD. Respiratory Medicine. 1999 Mar 1;93(3):202–7.

10. Collins JA, Rudenski A, Gibson J, Howard L, O'Driscoll R. Relating oxygen partial pressure, saturation and content: the haemoglobin–oxygen dissociation curve. Breathe (Sheff). 2015 Sep;11(3):194–201.

11. Diagnostic accuracy of venous blood gases compared to arterial blood gases | European Respiratory Society [Internet]. [cited 2023 Dec 12]. Available from: https://erj.ersjournals.com/content/42/Suppl_57/P3987

12. Plüddemann A, Thompson M, Heneghan C, Price C. Pulse oximetry in primary care: primary care diagnostic technology update. Br J Gen Pract. 2011 May;61(586):358–9.

13. Chan ED, Chan MM, Chan MM. Pulse oximetry: Understanding its basic principles facilitates appreciation of its limitations. Respiratory Medicine. 2013 Jun;107(6):789–99.

14. Wearable Technology Market Size & Industry Trends, 2032 [Internet]. [cited 2025 Dec 25]. Available from: https://www.fortunebusinessinsights.com/wearable-technology-market-106000

15. Windisch P, Schröder C, Förster R, Cihoric N, Zwahlen DR. Accuracy of the Apple Watch Oxygen Saturation Measurement in Adults: A Systematic Review. Cureus. 15(2):e35355.

16. Assessment of Non-Invasive Measurements of Oxygen Saturation and Heart Rate with an Apple Smartwatch: Comparison with a Standard Pulse Oximeter [Internet]. [cited 2025 Jun 23]. Available from: https://www.mdpi.com/2077-0383/11/6/1467

17. Assessment of Apple Watch Series 6 pulse oximetry and electrocardiograms in a pediatric population | PLOS Digital Health [Internet]. [cited 2025 Jun 23]. Available from: https://journals.plos.org/digitalhealth/article?id=10.1371/journal.pdig.0000051

18. Pätz C, Michaelis A, Markel F, Löffelbein F, Dähnert I, Gebauer RA, et al. Accuracy of the Apple Watch Oxygen Saturation Measurement in Adults and Children with Congenital Heart Disease. Pediatr Cardiol. 2023 Feb 1;44(2):333–43.

19. An assessment of the accuracy of pulse oximeters - Milner - 2012 - Anaesthesia - Wiley Online Library [Internet]. [cited 2023 Dec 12]. Available from: https://associationofanaesthetists-publications.onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2044.2011.07021.x

20. Wilson BJ, Cowan HJ, Lord JA, Zuege DJ, Zygun DA. The accuracy of pulse oximetry in emergency department patients with severe sepsis and septic shock: a retrospective cohort study. BMC Emerg Med. 2010 May 5;10:9.

21. Bhutta BS, Alghoula F, Berim I. Hypoxia. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025 Jan 26]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK482316/

22. Valbuena VSM, Seelye S, Sjoding MW, Valley TS, Dickson RP, Gay SE, et al. Racial bias and reproducibility in pulse oximetry among medical and surgical inpatients in general care in the Veterans Health Administration 2013-19: multicenter, retrospective cohort study. BMJ. 2022 Jul 6;378:e069775.

23. Jung H, Kim D, Lee W, Seo H, Seo J, Choi J, et al. Performance evaluation of a wrist-worn reflectance pulse oximeter during sleep. Sleep Health. 2022 Oct 1;8(5):420–8.

24. Temirbekov D, Güneş S, Yazıcı ZM, Sayın İ. The Ignored Parameter in the Diagnosis of Obstructive Sleep Apnea Syndrome: The Oxygen Desaturation Index. Turk Arch Otorhinolaryngol. 2018 Mar;56(1):1–6.

25. Landsberg R, Friedman M, Ascher-Landsberg J. Treatment of hypoxemia in obstructive sleep apnea. Am J Rhinol. 2001;15(5):311–3.

26. Horakova L, Roubik K. Performance of Different Pulse Oximeters Can Affect the Duration of Field Breathing Experiments. In: 2019 E-Health and Bioengineering Conference (EHB) [Internet]. 2019 [cited 2025 Dec 27]. p. 1–4. Available from: https://ieeexplore.ieee.org/document/8969917

27. DeMeulenaere S. Pulse Oximetry: Uses and Limitations. The Journal for Nurse Practitioners. 2007 May 1;3(5):312–7.

28. Rafl J, Bachman TE, Rafl-Huttova V, Walzel S, Rozanek M. Commercial smartwatch with pulse oximeter detects short-time hypoxemia as well as standard medical-grade device: Validation study. Digit Health. 2022 Oct 11;8:20552076221132127.

29. Santos M, Vollam S, Pimentel MA, Areia C, Young L, Roman C, et al. The Use of Wearable Pulse Oximeters in the Prompt Detection of Hypoxemia and During Movement: Diagnostic Accuracy Study. Journal of Medical Internet Research. 2022 Feb 15;24(2):e28890.

30. Arslan B, Sener K, Guven R, Kapci M, Korkut S, Sutasir MN, et al. Accuracy of the Apple Watch in measuring oxygen saturation: comparison with pulse oximetry and ABG. Ir J Med Sci. 2024 Feb;193(1):477–83.

31. Bengtsson J, Bake B, Johansson A, Bengtson JP. End-tidal to arterial oxygen tension difference as an oxygenation index. Acta Anaesthesiol Scand. 2001 Mar;45(3):357–63.

32. Jiang Y, Spies C, Magin J, Bhosai SJ, Snyder L, Dunn J. Investigating the accuracy of blood oxygen saturation measurements in common consumer smartwatches. PLOS Digit Health. 2023 Jul 12;2(7):e0000296.

33. Goldsack JC, Coravos A, Bakker JP, Bent B, Dowling AV, Fitzer-Attas C, et al. Verification, analytical validation, and clinical validation (V3): the foundation of determining fit-for-purpose for Biometric Monitoring Technologies (BioMeTs). npj Digit Med. 2020 Dec;3(1):55.

34. Health C for D and R. Pulse Oximeters - Premarket Notification Submissions [510(k)s]: Guidance for Industry and Food and Drug Administration Staff [Internet]. FDA; 2024 [cited 2024 May 30]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pulse-oximeters-premarket-notification-submissions-510ks-guidance-industry-and-food-and-drug

35. 510(k) Premarket Notification [Internet]. [cited 2022 Mar 3]. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K201456

36. Benni PB, MacLeod D, Ikeda K, Lin HM. A validation method for near-infrared spectroscopy based tissue oximeters for cerebral and somatic tissue oxygen saturation measurements. J Clin Monit Comput. 2018 Apr;32(2):269–84.

37. Severinghaus JW. Simple, accurate equations for human blood O2 dissociation computations. J Appl Physiol Respir Environ Exerc Physiol. 1979 Mar;46(3):599–602.

38. Whenn CB, Wilson DL, Ruehland WR, Churchward TJ, Worsnop C, Tolson J. The impact of study type and sleep measurement on oxygen desaturation index calculation. Journal of Clinical Sleep Medicine. 20(5):709–17.

39. Chardon A, Cretois I, Hourseau C. Skin colour typology and suntanning pathways. Int J Cosmet Sci. 1991 Aug;13(4):191–208.

40. Del Bino S, Bernerd F. Variations in skin colour and the biological consequences of ultraviolet radiation exposure. Br J Dermatol. 2013 Oct;169:33–40.

41. BTS guideline for emergency oxygen use in adult patients | Thorax [Internet]. [cited 2023 Dec 12]. Available from: https://thorax.bmj.com/content/63/Suppl_6/vi1

42. Henry NR, Hanson AC, Schulte PJ, Warner NS, Manento MN, Weister TJ, et al. Disparities in hypoxemia detection by pulse oximetry across self-identified racial groups and associations with clinical outcomes. Crit Care Med. 2022 Feb 1;50(2):204–11.

43. Health C for D and R. Pulse Oximeters for Medical Purposes - Non-Clinical and Clinical Performance Testing, Labeling, and Premarket Submission Recommendations [Internet]. FDA; 2025 [cited 2025 Jun 5]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pulse-oximeters-medical-purposes-non-clinical-and-clinical-performance-testing-labeling-and

44. Apple Inc. Blood Oxygen app on Apple Watch [Internet]. 2022. Available from: www.apple.com/healthcare/docs/site/Blood_Oxygen_app_on_Apple_Watch_October_2022.pdf

45. The desaturation response time of finger pulse oximeters during mild hypothermia* - MacLeod - 2005 - Anaesthesia - Wiley Online Library [Internet]. [cited 2024 Jun 9]. Available from: https://associationofanaesthetists-publications.onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2044.2004.04033.x

46. Khairunnisa S, Soesanti I, Listyarifah D. Classification of finger pulse oximeter based on their response time using quantitative analysis. Kristina SA, Hsu MH, Syahrom A, Ismail H, Vo TQ, editors. BIO Web Conf. 2023;75:02002.

47. Products - Data Briefs - Number 63, June 2011 [Internet]. 2019 [cited 2025 Jan 26]. Available from: https://www.cdc.gov/nchs/products/databriefs/db63.htm

48. Allen J, Murray A. Age-related changes in the characteristics of the photoplethysmographic pulse shape at various body sites. Physiol Meas. 2003 Mar;24(2):297.

49. Dewan NA, Nieto FJ, Somers VK. Intermittent Hypoxemia and OSA. Chest. 2015 Jan;147(1):266–74.

50. Iliaz S, Cagatay T, Bingol Z, Okumus G, Iliaz R, Kuran G, et al. Does the 6-minute walk test predict nocturnal oxygen desaturation in patients with moderate to severe COPD? Chron Respir Dis. 2015 Feb;12(1):61–8.

51. Chaouat A, Weitzenblum E, Kessler R, Charpentier C, Ehrhart M, Levi-Valensi P, et al. Sleep-related O2 desaturation and daytime pulmonary haemodynamics in COPD patients with mild hypoxaemia. Eur Respir J. 1997 Aug;10(8):1730–5.

52. Khondakar KR, Kaushik A. Role of Wearable Sensing Technology to Manage Long COVID. Biosensors (Basel). 2022 Dec 31;13(1):62.